The impact of flavonoids on fatigue has not been investigated in Relapsing and Remitting Multiple 3
fatigability are difficult to treat and greatly affect health related quality of life in pwMS [2] . 26
Fatigability is a term derived from the broader definition of fatigue which refers to an inability to 27 maintain both physical and cognitive performance [3] . The aetiology of fatigue in MS is complex 28 including possible neural, inflammatory, metabolic and psychological mechanisms [2] [4] . Whilst a 29 number of behavioural and drug approaches for fatigue management have been explored, to date the 30 strongest evidence of success in reducing MS related fatigue is from exercise interventions [5] [6] . 31
However success is limited and other approaches or combination therapies need to be investigated [7] . 32
Dark chocolate containing 70-85% cocoa solids is well known for its high antioxidant and 33 flavonoid content. Over a four week period, dark chocolate consumption has been shown to improve 34 subjective fatigue in those with Chronic Fatigue Syndrome (CFS) [8] [9], and results from a small 35 randomised controlled pilot study using a short-term cocoa intervention suggested an increase in sleep 36 quality and reduction in fatigue [10] . A simple dietary supplement could be implemented alongside 37 other behavioural interventions early after diagnosis as an adjunctive therapeutic approach to support 38 pwMS to manage fatigue. There is currently limited evidence-based guidance to inform tailored 39 We propose that a flavonoid approach for managing MS related fatigue may be moderately 45 effective, inexpensive, and safe [15] and that it may be exerting its effects by reducing inflammation 46 and oxidative stress. The aim of the current trial was to evaluate the feasibility and estimate potential 47 also recorded. Appropriateness of data collection methods was determined through completion of 110 questionnaires and missing data, and through the process evaluation, and estimates of effect {effect 111 sizes (ES) and confidence intervals (CI)} were calculated for the measures and demographics were 112 collected at baseline. 113
114

Fatigue and fatigability 115
Throughout the six-week intervention participants were asked to rate their level of fatigue on a 116 numerical rating scale (NRS) through daily 'fatigue texts' sent at 10:00, 15:00 and 20:00 every day, 117 rating their fatigue between 1-10 (10 worst). They replied to the text message of 'on a scale from 1-118 10, with 1 being no fatigue and 10 being the worst fatigue you have experienced, how fatigued are 119 you at the current time?'. They did this at 10 am, 3 pm and 8 pm every day for six weeks. Fatigability 120 was measured at baseline and week 6 using the six minute walk test (6MWT) [18] . Participants were 121 asked to walk at their normal, comfortable walking pace back and forth on a measured 16-metre track 122 in a University corridor. Distance walked was measured. At baseline, week 3 and 6 the levels of 123 subjective fatigue experienced over the past seven days were measured using the Neuro-QOL short 124 form questionnaire [19] . The Adult Memory and Information Processing Battery (AMIBP) [20] was 125 used to measure cognitive fatigue. The AMIPB required the second highest number in each row to be 126 
Process evaluation 142
Upon exiting the study at week 6, each participant was interviewed about the intervention process, 143 ease of adherence, tolerance and acceptability of the flavonoid drink and the collection of outcome 144 measures. Participants were asked their opinion on the importance of the research question proposed 145 to inform future trials. The thirteen topics used included difficulties with intervention delivery, 146 scheduling of assessments and outcome measure acceptability and suggestions on how to improve the 147 intervention process. A proportion of the data (20%) was coded by two different team members to 148 check on reliability of the coding scheme. Transcripts of interviews were examined to identify themes 149 and categories. Codes were applied to these broad themes, which were then broken down further into 150 sub-codes. Agreement on concepts and coding by blinded assessors were sought between two 151 members of the research team to ensure reliability. 152
153
Analysis 154
Feasibility was analysed through evaluation of eligibility, recruitment and retention [26] . 155
Completeness of outcome measures was reported and 80% was set as a criterion for success. 156
Retention was measured by the proportion of participants who were lost to follow-up. Successful 157 adherence to the intervention was defined as at least 75% of the participants having completed cocoa 158 consumption. Further aspects of adherence were measured by the percentage of fatigue texts 159 completed by participants. 160
Primary analysis followed the intention to treat principal utilised the complete case data set. 161
Results were presented using point estimates and 95% confidence intervals. For the fatigue texts the 162 fatigue NRS was calculated as the area under the curve (AUC) for each group, ignoring area beneath7 the baseline, and was calculated geometrically [27] . Data was transformed to improve model fit, or 164 different regression approaches were used (e.g. Negative Binomial, or Poisson regression). The results 165 for the 6MWT are reported as mean ± SD and for the comparison of baseline and post-intervention as 166 mean difference ± standard error [(SE); 95% (CI)]. A Linear Mixed Model (LMM) was used to 167 differences between groups throughout all time points. Alternatively and wherever the variables were 168 categorical, such as the EQ5D-5L sub categories, a generalized estimating equation (GEE) with 169 appropriate distributions (e.g. Negative Binomial) method was implemented. Both methods used 170 SAS/STAT 14.3. Fatigue and fatigability measures including the Neuro-QoL short form fatigue, the 171 6MWT and the AMIPB were further analysed to determine difference between responders and non-172 responders and relative risk scores then calculated. Responders on the NeuroQol, for both the control 173 and intervention groups, were classified as those who had a clinically meaningful change of 10 points 174 out of 100 (with the questionnaire total score converted from an original total of 40 between baseline 175 and week 6. Responders on the 6MWT were classified as those who had a minimally important 176 change (MIC) in covered distance of 21.6m [27] between baseline and week 6. 177
Data over three time points for activity data was analysed using a Freidman's test and 178 between group effects were calculated using a Mann-Witney test. Process evaluation included 179 frequencies for adhering to the intervention, session content and progression which was analysed 180 descriptively with confidence intervals and regression where possible. A standard content analysis 181 techniques were employed. Fifty-three people showed an initial interest in the trial, but decided not to take part due to: not having 196 enough time to take part in the trial, did not like chocolate, or were unable to take part in nutrition 197 trials due to being on weight loss programs or having gastric surgery. All but one person consumed 198 the cocoa with rice milk (one consumed almond milk). One person discontinued the control 199 intervention but was not lost to follow up and one person consented to be on the trial but decided not 200 to consume the cocoa from the start of the intervention. Adherence to intervention overall was 100% 201 QoL EQ5D-5L Mobility 2 ± 3 2 ± 3 1.5 ± 3 1 ± 2 1 ± 2 1 ± 2 -0.02 (-0.26-0.22) Self-care 1 ± 2 1 ± 2 1 ± 2 1 ± 1 1 ± 1 1 ± 1 -0.30 (-0.43-0.16) Usual activities 2 ± 3 2 ± 2 2 ± 3 2 ± 2 2 ± 2 2 ± 2 -0.12 (-0.33-0.11) Pain/ discomfort 2 ± 3 2 ± 3 2 ± 3 2 ± 3 2 ± 2 2 ± 3 -0.25 (-0.45-0.02) Anxiety/ depression 1 ± 2 1 ± 2 1 ± 2 2 ± 2 2 ± 2 2 ± 2 0.15 ( 0.14 (-0.31-0.58) PBMSI Walking 2 ± 2 2 ± 2 1.5 ± 2 1 ± 2 1 ± 2 1.5 ± 2 -0.15 (-0.35-0.07) Fatigue 2 ± 2 2 ± 2 2 ± 2 2 ± 2 2 ± 2 2 ± 2 -0.12 (-0.29-0.06) Mood 1 ± 2 1 ± 2 1 ± 2 1 ± 2 1 ± 2 1 ± 2 -0.10 (-0.30-0.11) Concentration 2 ± 3 2 ± 2 2 ± 2 2 ± 2 2 ± 2 2 ± 2 0.05 (-0. variables, using SAS 9.4 and Cliff's delta, for categorical variables, using R 3.5.
288
c. Relative risks were calculated for measure of fatigue and fatigability for responders versus non responders.
289
[Insert Table 3 ] 290 291 292 
Fatigue and fatigability 314
Fatigue was further analysed to determine difference between responders and non-responders. There 315 was no difference in means between groups (p>0.05) yet the Relative Risk (RR) for those who 316 responded and therefore had improved fatigue in the intervention group (11 out of 19 responders) to 317 the control group (8 out of 20 responders) was 1.45. The AMIPB was assessed in a similar way with a 318 change in 1 SD of an improvement in 11.5 seconds considered clinically meaningful. Based on these 319 criteria only one person improved in the intervention group and no one in the control group and 320 therefore a RR was not calculated. 321 There was a medium effect size for distance walked in six minutes (0.45 {CI 0.18-1.07}) 322 between the groups with the intervention showing a larger increase in the metres walked in 6 minutes 323 after the intervention (Table 2 ). The RR for responders in the intervention group compared to control 324 was 1.80 in favour of the intervention group. 325
326
Process evaluation 327
Both groups had similar positive experiences about the scheduling of the assessments. 13/19 in the 328 intervention vs 18/20 people in the control indicated no impact of the measurement instruments used 329 on weekly routine over the six weeks. Similar numbers in both groups identified that the outcome 330 measures were acceptable. Randomisation: Most comments from both groups indicated acceptance 331 towards the process of randomisation. Taste propose that considering the possible anti-inflammatory mechanism, flavonoids may be used as an 356 adjunctive approach alongside other therapeutic interventions and suggest the possible benefit of such 357 combined approaches for fatigue management. However further full powered trials would need to be 358
performed. 359
The time post diagnosis was extended from five to ten years in order to recruit to target (n = 360 40). Adherence (>75%), retention and amount of missing data (<80%) were within the acceptable 361 ranges. Most missing data was from the NRS texts over the six weeks which is not surprising as this 362 was the most time-consuming part of the assessment. Completion was still above 80% of total with 363 the first five weeks, with week six showing the most missing data. Mild AEs have previously been 364 reported when consuming high flavonoid cocoa including nausea and vomiting, gastrointestinal 365 disturbances and headaches [28] . The AEs reported in the current trial did not cause any safety 366 concerns and were similar between groups. 367 This is the first study to suggest the potential for fatigability being improved through a 368 6MWT after six weeks of a flavonoid intervention, with a moderate effect size. In the current study 369 the intervention showed a MIC over time with 33.7m (SE: 8.4 ) in contrast to the control group 10.2m 370 (SE: 9.6). Fatigue correlates with a decrease of physical endurance [29] and walking speed [30] and 371 therefore a treatment targeting fatigue could also improve walking performance. Flavonoid have been 372 found to increase cerebral blood flow by inducing widespread stimulation of brain perfusion, and this 373 could also influence mood, cognitive performance, fatigue perception and ability to perform specific 374 movement tasks [31] . When considering other symptoms, pain was shown to improve in the flavonoid 375 group over the six weeks as measured by the EQ5D-5L with a moderate effect size. The antioxidant 376
properties of flavonoids are thought to lesson neuropathic pain by alleviating oxidative stress and thus 377 reducing neuron damage caused by lipid peroxidation. [32] . We did not measure objective measures 378 of pain in this trial and therefore further research is warranted to explore the pain improvement. 379
Indeed previous research has pointed towards higher motivation in physical activity in pwMS when 380 symptoms such as pain were improved [33] . This may also allow pwMS to become more active and 381 mobile, as noted by the improvements on the 6MWT. 382
The process evaluation revealed that overall the trial was well accepted, with the timing of 383 assessments and the outcome measures being convenient and low burden, respectively and the 384 participants in both groups found the taste of the cocoa enjoyable, or noted it as neither tasty nor 385 unacceptable. In both groups the blinding and randomisation process were accepted, and a majority of 386 pwMS in both groups declared their willingness to continue consuming the cocoa long term, 387 especially if benefits to fatigue were found. However findings around the preparation of the drink and/ 388 or scheduling the timing of drink consumption into ones routine are factors to consider for future 389 trials. 390
391
Limitations 392
As a feasibility study a powered investigation using a sample size of 80 is now needed. For blood 393 measures, the lack of ability of the phlebotomist to collect blood from several of the participants led to 394 missing data. From the data collected, there were small effect sizes in blood indicators, apart from 395 lipid peroxidation which showed a moderate effect size and therefore this area needs further 396 investigation. The NRS fatigue data was analysed as a total whole change over the six weeks, and 397 therefore more sensitive analysis may have discovered changes within the six weeks. Fatigue may be 398 both physical and cognitive and coexists with and is impacted by a number of factors including 399 anxiety and depression. This study measured a number of these factors including: motor (6MWT) and 400 cognitive (AMIPB) fatigue, and anxiety and depression (HADS) which could be further investigated 401 in a study powered for this. In this pilot we set out to reduce variability from these factors where 
